GTHX - G1 Therapeutics Inc Stock Price, Fair Value and News

$7.15

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GTHX Price Action

Last 7 days

0.3%

Last 30 days

1.0%

Last 90 days

157.2%

Trailing 12 Months

346.9%

GTHX RSI Chart

GTHX Valuation

Market Cap

377.2M

Price/Earnings (Trailing)

-8.43

Price/Sales (Trailing)

6.48

EV/EBITDA

-11.13

Price/Free Cashflow

-10.05

GTHX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GTHX Fundamentals

GTHX Revenue

Revenue (TTM)

58.2M

Rev. Growth (Yr)

-60.97%

Rev. Growth (Qtr)

14.3%

GTHX Earnings

Earnings (TTM)

-44.8M

Earnings Growth (Yr)

-162.79%

Earnings Growth (Qtr)

46.48%

GTHX Profitability

EBT Margin

-73.83%

Return on Equity

-182.05%

Return on Assets

-45.36%

Free Cashflow Yield

-9.95%

GTHX Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-0.85

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	84.0M	58.2M	0	0
2023	57.3M	89.2M	77.9M	82.5M
2022	24.2M	28.1M	46.8M	51.3M
2021	59.5M	64.0M	42.2M	31.5M
2020	0	15.4M	30.4M	45.3M
2015	0	0	0	522.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About G1 Therapeutics Inc

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

CEO	Mr. John E. Bailey Jr.
WEBSITE	g1therapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	170

G1 Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for G1 Therapeutics Inc? What does GTHX stand for in stocks?

GTHX is the stock ticker symbol of G1 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of G1 Therapeutics Inc (GTHX)?

As of Wed Sep 18 2024, market cap of G1 Therapeutics Inc is 377.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GTHX stock?

You can check GTHX's fair value in chart for subscribers.

Is G1 Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GTHX is over valued or under valued. Whether G1 Therapeutics Inc is cheap or expensive depends on the assumptions which impact G1 Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GTHX.

What is G1 Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, GTHX's PE ratio (Price to Earnings) is -8.43 and Price to Sales (PS) ratio is 6.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GTHX PE ratio will change depending on the future growth rate expectations of investors.